Company news

Spero Therapeutics, Inc. news in 2025

Spero Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

December 19, 2025

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 28, 2025

Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

November 13, 2025

Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

November 4, 2025

PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

October 21, 2025

Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek

October 14, 2025

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

August 12, 2025

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

August 5, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

May 28, 2025

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

May 13, 2025

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

April 28, 2025

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

March 27, 2025

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

March 18, 2025

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

February 25, 2025

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

February 25, 2025

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

January 9, 2025

Calls in 2025

Decks in 2025